Flavan-based phytoconstituents inhibit Mpro, a SARS-COV-2 molecular target, in silico

Author(s):  
Soham Mukherjee ◽  
Deepika Sharma ◽  
Ajay Kumar Sharma ◽  
Shreya Jaiswal ◽  
Nancy Sharma ◽  
...  
Keyword(s):  
2021 ◽  
Vol 7 (19) ◽  
Author(s):  
Isabela Sacienti Lavezo ◽  
Juracy Cirino de Souza Neto ◽  
Túlio Nunes Pinto ◽  
Leonardo Luiz Borges

Lung cancer kills the most men and the second that kills the most women (behind only breast cancer). The in silico study makes it possible to search for new drugs at low cost, with a greater possibility of rapid manufacturing and a lower future cost for their manufacture. The objective of this study was to analyze an antineoplastic activity of the compounds of Artemisia annua to obtain an active substance that can reach the molecular target of the cancer cells. Compounds with antineoplastic effects were selected using Scielo, PubMed, and ScienceDirect platforms. Afterward, the first screening of compound compounds was performed with a high ability to predict biological and pharmacological activity through the PASS Prediction, Pubchem, and Swiss ADME platforms. After the current screening, we determined the toxicological and molecular target prediction by the Portox II and Swiss Target Prediction platforms. As a final part, molecular docking and redocking were performed for a compound using the PDB server and the GOLD Suite 5.7.0 program. For another, we completed the pharmacophoric mapping using the Binding DB and PharmaGist database. The compounds scopoletin and caffeic acid were the most promising structures in silico models capable of interacting with EGFR (epidermal growth factor) and MM-9 (metalloproteinase type 9), respectively. The results obtained that these structures are promising to be tested in in vitro and in vivo tests about the antineoplastic activity. In addition, in silico analyses help to understand the biological effects of A. annua extracts regarding antineoplastic evidence.


2020 ◽  
Vol 14 (12) ◽  
pp. 3083-3099 ◽  
Author(s):  
Jeremy Ariey‐Bonnet ◽  
Kendall Carrasco ◽  
Marion Le Grand ◽  
Laurent Hoffer ◽  
Stéphane Betzi ◽  
...  

Molecules ◽  
2020 ◽  
Vol 25 (6) ◽  
pp. 1316 ◽  
Author(s):  
Katharigatta N. Venugopala ◽  
Pushpalatha Ramachandra ◽  
Christophe Tratrat ◽  
Raquel M. Gleiser ◽  
Subhrajyoti Bhandary ◽  
...  

Malaria, affecting all continents, remains one of the life-threatening diseases introduced by parasites that are transmitted to humans through the bites of infected Anopheles mosquitoes. Although insecticides are currently used to reduce malaria transmission, their safety concern for living systems, as well as the environment, is a growing problem. Therefore, the discovery of novel, less toxic, and environmentally safe molecules to effectively combat the control of these vectors is in high demand. In order to identify new potential larvicidal agents, a series of 2-aryl-1,2-dihydroquinazolin-4-one derivatives were synthesized and evaluated for their larvicidal activity against Anopheles arabiensis. The in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the compounds were also investigated and most of the derivatives possessed a favorable ADMET profile. Computational modeling studies of the title compounds demonstrated a favorable binding interaction against the acetylcholinesterase enzyme molecular target. Thus, 2-aryl-1,2-dihydroquinazolin-4-ones were identified as a novel class of Anopheles arabiensis insecticides which can be used as lead molecules for the further development of more potent and safer larvicidal agents for treating malaria.


Antibiotics ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 247 ◽  
Author(s):  
Katharigatta N. Venugopala ◽  
Christophe Tratrat ◽  
Melendhran Pillay ◽  
Fawzi M. Mahomoodally ◽  
Subhrajyoti Bhandary ◽  
...  

Novel series of diversely substituted indolizines were designed, synthesized, and evaluated for their in vitro anti-mycobacterial activity against H37Rv and multi-drug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB). Many compounds exhibited significant inhibitory activity against MTB H37Rv strains. Indolizines 2d, 2e, and 4 were also found to be active against MTB clinical isolates with multi-resistance to rifampicin and isoniazid. Indolizine 4 was identified as the most promising anti-mycobacterial agent, displaying minimum inhibitory concentration (MIC) values of 4 and 32 μg/mL against H37Rv and MDR strains, respectively. Furthermore, an in silico study was carried out for prospective molecular target identification and revealed favorable interactions with the target enzymes CYP 121, malate synthase, and DNA GyrB ATPase. None of the potent molecules presented toxicity against peripheral blood mononuclear (PBM) cell lines, demonstrating their potentiality to be used for drug-sensitive and drug-resistant tuberculosis therapy.


2016 ◽  
Vol 25 (7) ◽  
pp. 1411-1419 ◽  
Author(s):  
Appadurai Daniel Reegan ◽  
Antony Stalin ◽  
Michael Gabriel Paulraj ◽  
Kedike Balakrishna ◽  
Savarimuthu Ignacimuthu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document